Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Two phase 3 trials are reshaping first-line treatment for advanced NSCLC with EGFR exon 20 insertions. PAPILLON showed amivantamab plus chemotherapy achieved a median overall survival exceeding 34 months — the longest reported for this patient group. REZILIENT3 found zipalertinib added to chemo cut progression risk by half, with a 6-month PFS improvement over chemo alone. Together with sunvozertinib data, clinicians now have multiple evidence-based frontline options.
Two phase 3 trials presented at the World Conference on Lung Cancer (WCLC) 2026 are adding meaningful options for patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertions — a molecularly complex subgroup that has historically resisted standard EGFR-targeted therapies.
In the PAPILLON trial's final overall survival (OS) analysis, amivantamab plus chemotherapy delivered a median OS of 34.3 months vs. 27.9 months with chemo alone — the longest reported OS for this population to date. While the 6.4-month numerical gain didn't reach statistical significance (likely influenced by 76% of chemo-arm patients crossing over to amivantamab), a crossover-adjusted model showed a significant OS benefit. In REZILIENT3, zipalertinib plus chemo cut the risk of progression nearly in half, with a median PFS of 14.5 vs. 8.5 months and a response rate of 65% vs. 40.3%.
Combined with earlier data on sunvozertinib monotherapy (WU-KONG28), clinicians now have three distinct phase 3-backed frontline regimens to choose from — none yet proven superior to the others.
By the Numbers
Why it matters: EGFR exon 20 insertions account for 5–12% of EGFR-mutant NSCLC and were once a therapeutic dead end. With three regimens now showing phase 3 benefit, treatment decisions will increasingly hinge on CNS activity, toxicity profile, route of administration, and patient preference — making individualized care more important than ever.
